Original Article

Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK/T-cell lymphoma

Young-Sun Nam1,2,3, Keon-Il Im1,3, Nayoun Kim1,3, Yunejin Song1,2,3, Jun-Seok Lee1,2,3, Young-Woo Jeon1,3,4, Seok-Goo Cho1,2,3,4

1Institute for Translational Research and Molecular Imaging, 2Department of Biomedicine and Health Sciences, The Catholic University of Korea, College of Medicine, Korea; 3Laboratory of Immune Regulation, Convergent Research Consortium for Immunologic Disease (CRCID), 4Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea

Received October 16, 2018; Accepted January 29, 2019; Epub March 15, 2019; Published March 30, 2019

Abstract: Epstein-Barr virus (EBV)-positive extranodal NK/T-cell lymphoma is a rare and highly aggressive disease with a poor prognosis and strong resistance to anti-cancer drugs. Reactive oxygen species (ROS) are closely related to tumorigenesis and P-glycoprotein (P-gp) is highly expressed in various cancers. However, the exact relationship between ROS and P-gp in EBV-positive lymphoma remains unclear. In this study, we demonstrated that EBV latent infection induced intracellular ROS production and increased ROS levels triggered elevated P-gp expression, which resulted in strong resistance to existing anti-cancer drugs in EBV-positive lymphoma cell lines and in patients’ tissue samples. We also verified that regulation of intracellular ROS reduced P-gp expression and function via inhibition of STAT1 phosphorylation. These results indicate that treatment with a ROS scavenger is a potential therapeutic strategy to overcome resistance to anti-cancer drugs by downregulating the expression of P-gp in EBV-positive NK/T-cell lymphoma.

Keywords: Epstein-Barr virus (EBV), extranodal NK/T-cell lymphoma (ENKTCL), reactive oxygen species (ROS), multi-drug resistance (MDR), P-glycoprotein (P-gp)

Introduction

Epstein-Barr virus (EBV) is a human gamma-herpes virus that exhibits three major latencies; I, II, and III and has been implicated in various tumors including lymphoma and gastric carcinoma [1-3]. Extranodal NK/T-cell lymphoma (ENKTCL), of which more than 95% of cases are EBV positive, shows a very poor prognosis and is characterised by distinct clinicopathological features including a low survival rate, metastasis [4], systemic inflammation [5] and drug resistance [4, 6]. It has been reported that various molecules are correlated with the poor prognosis and cell signalling pathways associated with an abnormal status in ENKTCL. EBV infection induces phosphorylation of molecules in the NF-κB, MAPK and JAK/STAT signalling pathways, resulting in tumor cell proliferation, angiogenesis and immune suppression [4, 7]. Patients with ENKTCL also showed mutations and/or methylation of tumor suppressor genes including PRDM1, ATG5, AIM1 [8], FOXO3 and HACE1 [9]. In clinical practice, ENKTCL is highly resistant to the existing anti-cancer drugs including anthracycline-based regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone). NK/T-cell lymphoma exhibits a multidrug-resistant (MDR) phenotype because of highly expressed P-glycoprotein (P-gp) [10]. To overcome this problem, MDR-independent drugs specifically designed for ENKTCL are now used. Therefore, concurrent chemo-radiotherapy regimens involving non-anthracycline chemotherapy using ifosfamide can improve treatment outcomes in patients by reducing local and systemic relapse rates, as explained in our previous report [11]. Also, to
overcome the immunological limitations of ENKTCL, we have been investigating other therapies using interferon alpha-2a [12] and EBV-specific cytotoxic T cells [13]. However, because there is still no complete cure, critical needs remain in the clinical treatment of ENKTCL.

In EBV-associated lymphoma, it has been reported that high ROS levels induced by EBV cause poor prognosis via deregulation of enzymes including catalase and peroxidase [14-16], gene instability [17-19] and modification of signalling pathways involved in anti-apoptotic effects and cell proliferation including NF-κB, MAPK and JAK/STAT [20-23]. Clinically, ENKTCL exhibits vascular damage and necrosis, which are closely related to high levels of ROS.

MDR is the major obstacle in cancer chemotherapy. Many cancers present resistance to anti-cancer drugs through the expression of P-gp, translated from the multidrug resistance protein 1 (MDR1) gene, which functions in an energy-dependent manner [24]. In various organs, P-gp expression induces the efflux of anti-cancer drugs. It has been reported that high levels of ROS induce P-gp expression [25, 26], hypoxia-inducible factor-1 (HIF-1) activation, nuclear translocation of NF-κB [27] and multicellular tumor spheroids [28] in various tumors. Patients with ENKTCL are positive for both P-gp and MDR1 mRNA and patients with high P-gp expression had poorer outcomes after chemotherapy alone [10]. In addition, it was demonstrated that EBV infection caused chemotherapy resistance through P-gp expression in EBV-positive T cell lymphoproliferative disease [29]. However, the direct mechanism of increased P-gp in ENKTCL remains unclear.

In this study, we examined the direct molecular pathological mechanisms of P-gp expression in EBV-positive NK/T-cell lymphoma, whether increased ROS induced by EBV infection upregulate the expression and function of P-gp, and which signalling pathways are involved in this process. We also investigated the possible use of the ROS scavenger NecroX-5 as an anti-cancer complement via its regulation of MDR in ENKTCL.

Materials and methods

Cell lines and materials

Of the cell lines used in this study, H9, Jurkat and Karpas-299 cells are EBV-negative T cell

Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

overcome the immunological limitations of ENKTCL, we have been investigating other therapies using interferon alpha-2a [12] and EBV-specific cytotoxic T cells [13]. However, because there is still no complete cure, critical needs remain in the clinical treatment of ENKTCL.

In EBV-associated lymphoma, it has been reported that high ROS levels induced by EBV cause poor prognosis via deregulation of enzymes including catalase and peroxidase [14-16], gene instability [17-19] and modification of signalling pathways involved in anti-apoptotic effects and cell proliferation including NF-κB, MAPK and JAK/STAT [20-23]. Clinically, ENKTCL exhibits vascular damage and necrosis, which are closely related to high levels of ROS.

MDR is the major obstacle in cancer chemotherapy. Many cancers present resistance to anti-cancer drugs through the expression of P-gp, translated from the multidrug resistance protein 1 (MDR1) gene, which functions in an energy-dependent manner [24]. In various organs, P-gp expression induces the efflux of anti-cancer drugs. It has been reported that high levels of ROS induce P-gp expression [25, 26], hypoxia-inducible factor-1 (HIF-1) activation, nuclear translocation of NF-κB [27] and multicellular tumor spheroids [28] in various tumors. Patients with ENKTCL are positive for both P-gp and MDR1 mRNA and patients with high P-gp expression had poorer outcomes after chemotherapy alone [10]. In addition, it was demonstrated that EBV infection caused chemotherapy resistance through P-gp expression in EBV-positive T cell lymphoproliferative disease [29]. However, the direct mechanism of increased P-gp in ENKTCL remains unclear.

In this study, we examined the direct molecular pathological mechanisms of P-gp expression in EBV-positive NK/T-cell lymphoma, whether increased ROS induced by EBV infection upregulate the expression and function of P-gp, and which signalling pathways are involved in this process. We also investigated the possible use of the ROS scavenger NecroX-5 as an anti-cancer complement via its regulation of MDR in ENKTCL.

Materials and methods

Cell lines and materials

Of the cell lines used in this study, H9, Jurkat and Karpas-299 cells are EBV-negative T cell

Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

overcome the immunological limitations of ENKTCL, we have been investigating other therapies using interferon alpha-2a [12] and EBV-specific cytotoxic T cells [13]. However, because there is still no complete cure, critical needs remain in the clinical treatment of ENKTCL.

In EBV-associated lymphoma, it has been reported that high ROS levels induced by EBV cause poor prognosis via deregulation of enzymes including catalase and peroxidase [14-16], gene instability [17-19] and modification of signalling pathways involved in anti-apoptotic effects and cell proliferation including NF-κB, MAPK and JAK/STAT [20-23]. Clinically, ENKTCL exhibits vascular damage and necrosis, which are closely related to high levels of ROS.

MDR is the major obstacle in cancer chemotherapy. Many cancers present resistance to anti-cancer drugs through the expression of P-gp, translated from the multidrug resistance protein 1 (MDR1) gene, which functions in an energy-dependent manner [24]. In various organs, P-gp expression induces the efflux of anti-cancer drugs. It has been reported that high levels of ROS induce P-gp expression [25, 26], hypoxia-inducible factor-1 (HIF-1) activation, nuclear translocation of NF-κB [27] and multicellular tumor spheroids [28] in various tumors. Patients with ENKTCL are positive for both P-gp and MDR1 mRNA and patients with high P-gp expression had poorer outcomes after chemotherapy alone [10]. In addition, it was demonstrated that EBV infection caused chemotherapy resistance through P-gp expression in EBV-positive T cell lymphoproliferative disease [29]. However, the direct mechanism of increased P-gp in ENKTCL remains unclear.

In this study, we examined the direct molecular pathological mechanisms of P-gp expression in EBV-positive NK/T-cell lymphoma, whether increased ROS induced by EBV infection upregulate the expression and function of P-gp, and which signalling pathways are involved in this process. We also investigated the possible use of the ROS scavenger NecroX-5 as an anti-cancer complement via its regulation of MDR in ENKTCL.

Materials and methods

Cell lines and materials

Of the cell lines used in this study, H9, Jurkat and Karpas-299 cells are EBV-negative T cell lines. NKL and KHYG-1 are EBV-negative NK cell lymphoma cell lines, and NK-92, NK-YS, KAI3, HANK-1 and SNK-6 are EBV-positive NK cell lymphoma cell lines. H9 cell is purchased from Korean Cell Line Bank (Seoul, Republic of Korea), KHYG-1 and KAI3 cells from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan), and NK-92 cells from the American Type Culture Collection (Manassas, VA, USA). Jurkat, Karpas-299, H9, NKL, KHYG-1 and KAI3 cells were grown in RPMI 1640 medium (Gibco, Carlsbad, CA, USA) containing 2 mM L-glutamine (Gibco), 1% 2-mercaptoethanol (Gibco), 1% antibiotics (10 U/mL penicillin and 10 g/mL streptomycin; Gibco), 10% heat-inactivated foetal bovine serum (FBS; Gibco) and 200 U/mL recombinant human IL-2 (rhIL-2, PeproTech, London, UK) were added to NKL, KHYG-1 and KAI3. NK-YS cells were cultured in IMDM medium (Gibco) containing 1% antibiotics (10 U/mL penicillin and 10 g/mL streptomycin), 10% heat-inactivated FBS and 100 U/mL rhIL-2. HANK-1 and SNK-6 cells were grown in RPMI 1640 medium containing 1% 2-mercaptoethanol (Gibco), 10% human serum (Sigma-Aldrich, St. Louis, MO, USA) and 100 U/mL and 700 U/mL rhIL-2, respectively. NK-92 cells were cultured in alpha-MEM medium (Gibco) containing 2 mM L-glutamate (Gibco), 1.5 g/L sodium bicarbonate (Gibco), 0.2 mM inositol (Sigma-Aldrich), 0.1 mM 2-mercaptoethanol (Gibco), 0.02 mM folic acid (Sigma-Aldrich), 12.5% FBS, 12.5% horse serum (Gibco) and 200 U/mL rhIL-2 (PeproTech). NecroX-5 (C₂₅H₃₁N₃O₃S·2CH₄O₃S) was purchased from Enzo Life Sciences (Farmingdale, NY, USA).

ROS assay

A solution of 2',7'-dichlorofluorescein diacetate (DCFDA; Sigma-Aldrich) in methanol (Bio-Lab, Jerusalem, Israel) was added at a final concentration of 2 μM to cell lines in phosphate-buffered saline (PBS). After a 40-min incubation at 37°C in a humidified atmosphere of 5% CO₂ in air, the cells were washed and resuspended in PBS.

Cell Counting Kit-8 (CCK-8) assay

Cell growth was assessed using the CCK-8 (Dojindo, Rockville, MD, USA) assay according to the manufacturer’s protocol. Briefly, 5 × 10⁴ lymphoma cells were dispensed in 100 μL culture medium in 96-well plates, and various
doses of anti-cancer drugs were diluted in 100 μL. Cultures were maintained at 37°C in a 5% CO₂ atmosphere. After 24 or 48 h, 20 μL CCK-8 solution was added to each well, and the plate was incubated for 1-4 h in a CO₂ incubator. The optical density was measured at 450 nm using a microplate reader.

**Flow cytometric analysis**

To investigate P-gp expression, lymphoma cells were immunostained with anti-human CD243 PE (P-gp; eBioscience, San Diego, CA, USA) for 30 min at 4°C. After staining, lymphoma cells were washed with staining buffer and resuspended in staining buffer. To investigate signaling pathways, lymphoma cells were pre-treated with 20 μM NecroX-5 for 30 min. Cells were washed and cultured at 37°C for 16 h. Intracellular staining with phospho-STAT1, STAT3, ERK1/2 and NF-κB (BioLegend, San Diego, CA, USA) was performed using an intracellular staining kit (eBioscience) according to the manufacturer’s protocol. Flow cytometric analysis was performed on the FACS_LSR Fortessa (BD Pharmingen, San Diego, CA, USA) using FlowJo software (TreeStar, Ashland, OR, USA).

**Western blot analysis**

Total protein was collected from cells pre-treated with or without 20 μM NecroX-5. Cells were homogenized by lysis buffer with a protease/phosphatase inhibitor cocktail (Cell signalling, Danvers, MA) and western blotting was performed. The primary antibody used was rabbit antibodies to P-gp (1:1000, ERP10364-53; Abcam, Cambridge, UK) and β-actin (1:2000, Cell signalling). After overnight incubation in 4°C, HRP-conjugated secondary antibody was added. After washing with Tris-buffered saline and Twenn 20, the hybridized bands were detected using an enhanced chemiluminescence (ECL) detection kit (Amersham Pharmacia Biotech, Buckinghamshire, UK).

**Rhodamine 123 (Rho123) accumulation assay**

NKL, NK-92 and NK-YS cells (5 × 10⁵) were grown on 24-well plates and pre-treated with NecroX-5 for 1 h at 37°C. The cells were then washed with PBS and stimulated with 125 μM H₂O₂ for 16 h. Rho123 (0.5 μg/mL) was added, and cells were incubated at 37°C for an additional 1 h in the presence or absence of H₂O₂. The cells were harvested, and the concentration of Rho123 was measured by flow cytometric analysis.

**EBV-encoded small RNA (EBER) in situ hybridization and immunohistochemistry (IHC)**

Patient biopsied lymphoma tissues were formalin-fixed, paraffin-embedded and sectioned at a thickness of 4 μm. Staining for EBERs was performed using the INFORM EBERs probe (Ventana, Tucson, AZ, USA) according to the manufacturer’s protocol. For IHC, slides were dehydrated using xylene and ethanol, and antigen retrieval and blocking were performed. Antibodies targeting P-gp (Abcam) was diluted 1:50 and then incubated with the slides at 4°C overnight. Anti-rabbit IgG-HRP (Santa Cruz Biotechnology) was used as the secondary antibody, and the slides were incubated at room temperature for 2 h. Signals were detected using the REAL EnVision detection system, peroxidase/DAB+ (Dako, Santa Clara, CA, USA). Counterstaining was performed using Mayer’s haematoxylin (Dako) for 1 min at room temperature.

**Real-time reverse transcription PCR (RT-PCR)**

Total RNA was extracted using TRIzol-LS reagent (Invitrogen). Total RNA was reverse transcribed using ReverTra Ace qPCR RT master mix (Toyobo, Osaka, Japan) according to the manufacturer’s protocol. RT-PCR was performed using the IQ SYBR Green Super Mix and CFX 96 real-time system (Bio-Rad, Hercules, CA, USA) under the following conditions: denaturation at 95°C for 3 min, annealing at 58°C for 30 s, followed by extension at 72°C for 30 s. For quantification, relative mRNA expression of specific genes was calculated using the 2^{-ΔΔct} method, after normalization to β-actin expression. The following gene-specific primers were used: β-actin (forward: 5’-GAA ATC GTG CGT GAC ATCAAA G-3’; reverse: 5’-TGT AGT TTC ATG GAT GCC ACA G-3’); and MDR1 (forward: 5’-CAG GAA CCT GTA TTG TTT GCC ACC AC-3’; reverse: 5’-TGC TTC TGC CCA CCA CTC AAT TG-3’).

**Statistical analysis**

All statistical analysis was performed using SPSS statistical software package (SPSS, Chicago, IL, USA). Statistical significance was
Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

Determined using student's two-tailed t-test and one-way analysis of variance (ANOVA) with Bonferroni correction for multiple comparisons. In all analysis, data are presented as means ± SD and P-values < 0.05 were considered to indicate significance.

Results

P-gp expression and ROS levels are elevated in EBV-positive NK/T-cell lymphoma

To determine the association between EBV and P-gp, EBV infection and P-gp expression were measured in lymphoma tissues from ENKTL patients using EBER in situ hybridization and IHC, respectively. Patients with negative for EBV infection showed low expression of P-gp (Figure 1A, UPN01). Interestingly, P-gp was highly expressed in the tissue areas with strong EBER expression (Figure 1A, UPN02, 03 and 04). Therefore, to examine the association between EBV and P-gp, firstly we investigated P-gp expression in various EBV-associated NK/T-cell lymphoma cell lines using flow cytometry analysis. EBV-negative T cell lymphoma cell lines (H9), EBV-negative NK cell lymphoma cell lines (KHYG-1 and NK-L) and EBV-positive NK cell lymphoma cell lines (HANK-1, KAI3, NK-YS, NK-92 and SNK-6) were used. Interestingly, compared with EBV-negative cells, EBV-positive cells showed higher P-gp expression. In NK-YS and NK-92 cells, P-gp expression was more than 10 times higher than that in KHYG-1 and NK-L cells (Figure 1B). The MDR1 mRNA level was also detected to confirm P-gp expression. As with P-gp expression, EBV-positive lymphoma cell lines, including NK-92 and NK-YS cells, showed higher MDR1 mRNA expression (Figure 1C). Although KHYG-1 showed higher MDR1 mRNA levels compared to two EBV-positive cell lines; KAI3 and HANK-1, P-gp expression was lower compared to EBV-positive cells.

Next, to investigate the relationships among EBV, ROS and P-gp, ROS levels in EBV-associated cell lines were measured by flow cytometry analysis.
Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

Figure 2. ROS levels in EBV-associated lymphoma cell lines. A. Intracellular ROS levels shown by the histogram using flow cytometry. B. Graph of MFI levels. Compared with EBV-negative cell lines, most EBV-positive T and NK cell lines showed higher MFI values. In some EBV-positive cell lines, intracellular ROS levels were more than threefold higher than those in EBV-negative cells. *P < 0.05, **P < 0.01, ***P < 0.001 vs. indicated group.

Inhibition of intracellular ROS levels downregulates P-gp expression

To investigate the direct relationship between ROS and P-gp, both EBV-negative and -positive NK cell lymphoma cell lines were treated with NecroX-5, a free radical scavenger. This indole backbone-based synthetic compound exhibited antioxidant effects in various disease models [30, 31] including graft versus host disease in our previous studies [32]. Cells were treated with 0, 10, 20 and 40 μM NecroX-5 for 2 hours, then washed and cultured for 16 hours. As shown in Figure 3A, ROS levels tended to decrease after treatment with NecroX-5, in a dose-dependent manner. Interestingly, NecroX-5 regulated ROS levels more significantly in EBV-positive lymphoma cell lines. After 16 hours, P-gp expression was detected by flow cytometry. In EBV-negative cell lines, NecroX-5 downregulated P-gp expression to some degree (Figure 3B). Although P-gp expression was reduced in NKL cells, NecroX-5 had less effect on P-gp regulation, because of the low P-gp expression in controls. In all EBV-positive cell lines, all doses of NecroX-5 downregulated P-gp expression (Figure 3B). NecroX-5 at 40 μM decreased P-gp from 7.62% to 3.51% and from 19.2% to 6.69% in SNK-6 and NK-92 cell lines, respectively. Interestingly, P-gp expression was dramatically decreased in NK-YS cells, from 18.9% to 1.66%, even at the lowest dose of NecroX-5 used. P-gp expression was also regulated by NecroX-5 in HANK-1 cells; however, because P-gp expression in NecroX-5-untreated cells was already low, the changes were not significant and it seems that the most effective dose of NecroX-5 appeared to differ from cell to cell. In NK-92 and NK-YS cells, 40 μM was the most effective dose for both ROS regulation and P-gp downregulation. In addition to these data, we confirmed that NecroX-5 was able to decrease P-gp expression analysed by western blot analysis in NKL, NK-92, NK-YS and HANK-1 cells (Figure S1). Similar to flow cytometry data, cell lines with high expression of P-gp; NK-92 and NK-YS showed decreased P-gp level after NecroX-5 treatment and in NKL, P-gp expression was rarely detected both in NecroX-5 untreated and pre-treated group. These results suggest that NecroX-5 decreased P-gp expression by regulating ROS.

P-gp function is attenuated by the regulation of intracellular ROS

To investigate whether ROS regulation directly affects P-gp function in EBV-positive lymphoma, we assessed accumulation of Rho123, the substrate of P-gp located in the mitochondria, after NecroX-5 treatment. In the case of low expression of P-gp, Rho123 was accumulated in intracellular space and in the case of high expression of P-gp, P-gp pumped out Rho123, therefore, Rho123 accumulation was reduced resulted in decreased fluorescence analysed by flow cytometry. We pre-treated lymphoma...
Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

Figure 3. The effects of ROS inhibition in P-gp expression. A. In EBV-negative cell lines, NecroX-5 did not affect intracellular ROS levels, whereas in EBV-positive cells, NecroX-5 regulated intracellular ROS in a dose-dependent manner. B. EBV-negative KHYG-1 and NKL cells were treated with various doses of NecroX-5 for 2 h. After 16 h of culture, P-gp expression was measured by flow cytometry. NecroX-5 regulated P-gp expression in NKL cells only. C. Compared to EBV-negative cell lines, dramatic regulation was shown at all doses of NecroX-5 in EBV-positive NK cell lymphoma cell lines including SNK-6, NK-92, NK-YS and HANK-1. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control group.
Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

cells with NecroX-5 and incubated at 37°C with Rho123. In EBV-negative cells, Rho123 showed high intracellular accumulation regardless of NecroX-5 treatment (Figure 4, upper panel) because of the lower expression of P-gp. In contrast, as shown in the lower panel of Figure 4, Rho123 showed high intracellular accumulation in EBV-positive NK cells. In NK-92 cells, the MFI for intracellular Rho123 was more than fourfold higher after NecroX-5 treatment. NecroX-5 also increased intracellular Rho123 accumulation in NK-YS cells, but not as dramatically as in NK-92 cells. The MFI of Rho123 was approximately threefold higher after NecroX-5 treatment. These results suggest that NecroX-5 directly reduced P-gp function.

Regulation of ROS promotes the cytotoxicity of anti-cancer drugs

Patients with EBV-positive NK/T-cell lymphoma are refractory to conventional anti-cancer drugs including P-gp-dependent drugs such as doxorubicin and cisplatin and P-gp-independent drugs including cyclophosphamide and methotrexate. To evaluate whether NecroX-5 increases the sensitivity to anti-cancer drugs, we treated EBV-negative and -positive lymphoma cell lines with various doses of NecroX-5. In EBV-negative cell lines, intracellular ROS inhibition affected cell viability in a dose-dependent manner (Figure 5A). A dose of 40 μM was sufficient to kill 50% of lymphoma cells. However, EBV-positive cell lines showed varying cytotoxicities toward NecroX-5. HANK-1 and SNK-6 cells showed similar patterns to those of EBV-negative cells. However, interestingly, two EBV-positive NK cell lines, NK-92 and NK-YS, which showed high expression of P-gp and ROS in previous experiments, were not significantly affected by NecroX-5 treatment. Next, we investigated the cytotoxic effects of anti-cancer drugs combined with NecroX-5 in EBV-positive cells (Figure 5B). In EBV-negative NKL cells, which showed low P-gp expression, four anti-cancer drugs (P-gp-dependent drugs doxorubicin and cisplatin and P-gp-independent drugs cyclophosphamide and methotrexate) showed high dose-dependent cytotoxic effects and even at the 1 μM dose of doxorubicin and methotrexate, half of the NKL cells were killed. However, there were no differences between NecroX-5-treated and -untreated cells. Interestingly, in EBV-positive NK-92 cells, P-gp-dependent cisplatin and two P-gp-independent drugs, cyclophosphamide and methotrexate, were ineffective regardless of NecroX-5 co-treatment. However, the cytotoxic effects of doxorubicin were significantly increased in NecroX-5-pre-treated cells even at low doses. Additionally, NecroX-5 pre-treated NK-YS cells were sensitive to doxorubicin, whereas they were dose-dependently sensitive to cisplatin regardless of NecroX-5 treatment. Cyclophosphamide and methotrex-
Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

Figure 5. The cytotoxic effects of NecroX-5 alone or with anti-cancer drugs. CCK-8 assay measuring cell viability for investigating the cytotoxic effects of NecroX-5. A. Although the cytotoxic effects of NecroX-5 varied by cell line, all EBV-negative cells were sensitive to NecroX-5 alone. However, in most EBV-positive cell lines, NecroX-5 alone was not sufficient to kill lymphoma cells. B. Lymphoma cell lines pre-treated with 40 μM NecroX-5 for 1 hour were cultured with four anti-cancer drugs for 48 h. In EBV-positive NK cell lymphoma cells, NecroX-5 enhanced the cytotoxic effects of the P-gp-dependent anti-cancer drugs doxorubicin and cisplatin. Dotted lines with empty circles indicate untreated cells, and dark lines with full squares indicate cells pre-treated with NecroX-5. *P < 0.05, **P < 0.01, ***P < 0.001 vs. NecroX-5 non-treated group.
Figure 6. The involvement of STAT1 phosphorylation after inhibition of intracellular ROS. A. In NKL cells, phosphorylation of NF-κB, but not STAT1, STAT3 or ERK1/2, was inhibited by NecroX-5. B. In NK-92 cells, NecroX-5 downregulated STAT1, STAT3, ERK1/2 and NF-κB expression. In NK-YS, only the STAT1 signalling pathway was regulated and NecroX-5 upregulated NF-κB phosphorylation. C. Under hypoxic conditions induced by H_2O_2 stimulation, STAT1 signalling was inhibited by NecroX-5. Grey histograms show untreated cells, and white histograms with dotted lines show NecroX-5-treated cells. *P < 0.05, **P < 0.01, ***P < 0.001 vs. NecroX-5 non-treated group.
Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

Inhibition of STAT1 phosphorylation downregulates P-gp expression

To investigate which signalling pathways are involved in regulating P-gp expression via NecroX-5 and whether there is a difference between EBV-negative and EBV-positive cell lines, NKL, NK-92 and NK-YS cells were pre-treated with various doses of NecroX-5 and stained for phospho-STAT1, STAT3, ERK1/2 and NF-κB. As shown in Figure 6A, there were no significant differences in STAT1, STAT3 or ERK1/2 phosphorylation after NecroX-5 treatment. Interestingly, NecroX-5 inhibited the phosphorylation of NF-κB (p65) in EBV-negative cells. In EBV-positive NK-92 cells, STAT1, STAT3, ERK1/2 and NF-κB phosphorylation were downregulated by NecroX-5 (Figure 6B, upper level). Both STAT1 and STAT3 phosphorylation were significantly decreased; the MFI of p-STAT1 decreased from 3073.5 to 1849.5 and that of STAT3 decreased from 1958.5 to 1323.5 following NecroX-5 treatment. The MFI of ERK1/2 phosphorylation was also downregulated from 1374 to 1055. Although NecroX-5 also inhibited NF-κB phosphorylation, this effect was not significant. In NK-YS cells, NecroX-5 did not affect the phosphorylation of STAT3 or ERK1/2 (Figure 6B, lower level). However, STAT1 phosphorylation was downregulated and NF-κB phosphorylation upregulated after NecroX-5 treatment. Therefore, we confirmed that NecroX-5 regulated STAT1 phosphorylation only in EBV-positive
lymphoma cells. To clarify whether NecroX-5 regulates the STAT1 signalling pathway under hypoxic conditions in EBV-positive lymphoma, we pre-treated cells with 20 μM NecroX-5 and stimulated them with H$_2$O$_2$ to establish hypoxic conditions. Interestingly, NecroX-5 significantly reduced STAT1 phosphorylation under hypoxic conditions in EBV-positive cells (Figure 6C). From these data, we determined that NecroX-5 regulated P-gp expression via the STAT1 signalling pathway.

Therefore, to clarify the relationship between STAT1 phosphorylation and P-gp expression, we used the STAT1-specific inhibitor fludarabine. Lymphoma cells were treated with various doses of fludarabine for 2 h. After inhibiting STAT1 phosphorylation with fludarabine, P-gp expression was reduced not only in EBV-positive but also EBV-negative cells (Figure 7). Although P-gp expression was decreased from 1.79% to 0.31% after treatment with 25 μM fludarabine, the effect was not significant, because the basal level of P-gp was low in EBV-negative NKL. In NK-92 cells, P-gp was down-regulated by fludarabine in a dose-dependent manner. P-gp expression was 25% in the resting state and was decreased to 21.7%, 19.9% and 18.1% following treatment with 5, 12.5 and 25 μM fludarabine, respectively. However, the effect was not statistically significant. Additionally, in NK-YS cells, another EBV-positive cell line, inhibition of STAT1 signalling via fludarabine treatment decreased P-gp expression from 29.1% to 14.9% (P < 0.05). Altogether, we concluded that STAT1 phosphorylation has a close relationship with high P-gp expression and NecroX-5 downregulated P-gp expression through inhibition of the STAT1 signalling pathway more effective compared to fludarabine.

Discussion

In this study, we first evaluated the direct relationships among EBV, ROS and P-gp. EBV infection caused hypoxic conditions, which in turn induced high levels of intracellular ROS. Increased intracellular ROS activated the STAT1 signalling pathway and phosphorylated STAT1 promoted P-gp expression resulting from $MDR1$ gene translation (Figure 8). P-gp-induced drug efflux resulted in reduced chemosensitivity.
Interestingly, NecroX-5 regulated the expression and function of P-gp via intracellular ROS regulation and therefore increased chemosensitivity to the P-gp-dependent anti-cancer drugs doxorubicin and cisplatin.

Whether high levels of ROS aggravate tumor conditions is a subject of controversy [33-35]. It has been reported that EBV-induced ROS lead to a poor prognosis via signalling pathway modifications, gene instability and deregulation of enzymatic functions. Cerimele and colleagues first reported that high ROS levels aggravated EBV-positive Burkitt’s lymphoma via VEGF production induced by MAPK phosphorylation [23]. EBNA1 promoted NF-κB activation by activating other viral genomes such as latent membrane protein 1 (LMP1), which is affected by highly expressed ROS levels [36] or ROS-induced EBV lytic gene expression via NF-κB and AP-1 signalling activation [22]. Additionally, there have been some reports that increased ROS levels after EBV infection promoted gene instability by DNA damage, inhibition of DNA repair [19] and telomere dysfunction [18]. Impairment of enzymes involved in intracellular ROS regulation, including malondialdehyde, catalase and superoxide dismutase, was reported in B cell lymphoma [15, 16] and in epithelial cells resulting in nasopharyngeal carcinomas [37-39]. In contrast, there are reports that upregulation of ROS induced tumor apoptosis and inhibited tumorigenesis in EBV-positive cancer. In EBV-infected B cells, high ROS expression induced apoptosis via centrosome/cenroblast marker 1 ligation [40] and Fas ligand upregulation by B7-H4 [41] and B7-H1 [42]. It has also been reported that intracellular ROS attenuated tumorigenesis via various signalling pathways, including the MAPK and JNK pathways [43-47], and activation of RhoA and Ras [48] and Tap73 and XAF1 [49]. Here, we demonstrated that high levels of intracellular ROS after EBV infection result in more aggressive tumor microenvironments.

In this study, we evaluated changes in various signalling pathway molecules including NF-κB, STAT and MAPK after NecroX-5 treatment to determine which signalling pathways are involved in the downregulation of P-gp by inhibiting intracellular ROS. As shown in Figures 6 and 7, we confirmed that inhibition of high phosphorylated STAT1 levels by NecroX-5 decreased P-gp expression, and STAT1 phosphorylation by the STAT1-specific inhibitor fludarabine downregulated P-gp in vitro. However, the mechanism about explaining why NecroX-5 is more effective than fludarabine remains to be studied. It has been reported that STAT1 phosphorylation is closely related to P-gp expression. Fryknaas and colleagues first observed a higher level of phosphorylated STAT1 in doxorubicin-resistant myeloma cells [50]. In addition, in lung cancer, etoposide resistance was induced by P-gp expression regulated by histone deacetylase 4 at the transcriptional level and by STAT1 at the post-transcriptional level [51]. Therefore, NecroX-5 may also be effective against lung cancer, as ROS have been linked to oxidation and nuclear efflux of histone deacetylase 4. Although the role of STAT1 phosphorylation in cancer has recently proven controversial, as it can act as both a tumor suppressor and tumor promoter [52], our study is meaningful in confirming that STAT1 phosphorylation induced by ROS aggravated EBV-positive lymphoma via P-gp overexpression and NecroX-5 may serve as a new anti-cancer complement. However, in NK-YS cells, after treatment of NecroX-5, the phosphorylation of NF-κB was increased, we hypothesized that this seemed to be due to the changes of intracellular ROS environment, however, more research is needed to understand.

In conclusion, based on this study, EBV latency infection induced high levels of intracellular ROS and highly-induced ROS upregulated P-gp via the STAT1 signalling pathway. Interestingly, we confirmed that the ROS scavenger NecroX-5 regulated the expression and function of P-gp and pre-treatment of NecroX-5 to ENKTCL patients with hypoxic condition could increase therapeutic effects of existing P-gp-dependent anti-cancer drugs; therefore, NecroX-5 may be a novel anti-cancer drug complement to overcome resistance to anti-cancer drugs in EBV-positive NK cell lymphoma.

Acknowledgements

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (No. NRF-2016R1A2B4007282).

Disclosure of conflict of interest

None.
Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

Address correspondence to: Dr. Seok-Goo Cho, Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary’s Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea; Institute for Translational Research and Molecular Imaging, The Catholic University of Korea, College of Medicine, 222, Banpo-daero, Seocho-gu, Seoul 06591, Korea; Tel: 82-2-2258-6052; Fax: 82-2-599-3589; E-mail: chosg@catholic.ac.kr

References


Down-regulation of P-gp in EBV-positive NK/T cell lymphoma


Down-regulation of P-gp in EBV-positive NK/T cell lymphoma


Down-regulation of P-gp in EBV-positive NK/T cell lymphoma

Figure S1. Reduction of P-gp expression after down-regulation of intracellular ROS using NecroX-5. Lymphoma cell lines were pre-treated with 20 μM NecroX-5 and cultured for protein expression. Total proteins were collected and western blot analyses for P-gp and β-actin were performed. In NK-92 and NK-YS cell lines, NecroX-5 was able to decrease P-gp expression significantly and in HANK-1 cell, P-gp expression was slightly reduced.